JP7048863B2 - 非アルコール性脂肪肝疾患の治療法 - Google Patents

非アルコール性脂肪肝疾患の治療法 Download PDF

Info

Publication number
JP7048863B2
JP7048863B2 JP2019511454A JP2019511454A JP7048863B2 JP 7048863 B2 JP7048863 B2 JP 7048863B2 JP 2019511454 A JP2019511454 A JP 2019511454A JP 2019511454 A JP2019511454 A JP 2019511454A JP 7048863 B2 JP7048863 B2 JP 7048863B2
Authority
JP
Japan
Prior art keywords
compound
dose
administered
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524860A5 (enExample
JP2019524860A (ja
Inventor
ハーナウアー ギード
洋 長袋
雄一郎 天野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2019524860A publication Critical patent/JP2019524860A/ja
Publication of JP2019524860A5 publication Critical patent/JP2019524860A5/ja
Application granted granted Critical
Publication of JP7048863B2 publication Critical patent/JP7048863B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019511454A 2016-08-26 2017-08-25 非アルコール性脂肪肝疾患の治療法 Active JP7048863B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380004P 2016-08-26 2016-08-26
US62/380,004 2016-08-26
PCT/EP2017/071418 WO2018037109A1 (en) 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease

Publications (3)

Publication Number Publication Date
JP2019524860A JP2019524860A (ja) 2019-09-05
JP2019524860A5 JP2019524860A5 (enExample) 2020-10-01
JP7048863B2 true JP7048863B2 (ja) 2022-04-06

Family

ID=59699703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511454A Active JP7048863B2 (ja) 2016-08-26 2017-08-25 非アルコール性脂肪肝疾患の治療法

Country Status (7)

Country Link
US (1) US11179384B2 (enExample)
EP (1) EP3503892A1 (enExample)
JP (1) JP7048863B2 (enExample)
CN (1) CN110099686B (enExample)
AU (1) AU2017317575B2 (enExample)
CA (1) CA3034956C (enExample)
WO (1) WO2018037109A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526283A (ja) 2004-03-03 2007-09-13 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のヒドロキシ−６−ヘテロアリールフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
WO2009109525A1 (en) 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001238288A1 (en) * 2000-02-16 2001-08-27 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
CN101133045A (zh) * 2005-03-02 2008-02-27 尼科梅德有限责任公司 6-杂环基取代的六氢菲啶衍生物的新盐类
NZ560268A (en) 2005-03-02 2010-12-24 Nycomed Gmbh Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
EP3096760A1 (en) * 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526283A (ja) 2004-03-03 2007-09-13 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のヒドロキシ−６−ヘテロアリールフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
WO2009109525A1 (en) 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
WO2009154230A1 (ja) 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Diabetologia，2012年，Vol.55，pp.2779-2788
J. Clin. Endocrinol. Metab.，2012年，Vol.97, No.9，pp.E1720-E1725
Nat. Rev. Gastroenterol. Hepatol.，2014年，Vol.11，pp.274-276
Obesity Reviews，2016年，Vol.17，pp.429-441

Also Published As

Publication number Publication date
WO2018037109A1 (en) 2018-03-01
US11179384B2 (en) 2021-11-23
EP3503892A1 (en) 2019-07-03
US20210283122A1 (en) 2021-09-16
CN110099686B (zh) 2022-04-15
CN110099686A (zh) 2019-08-06
CA3034956C (en) 2024-10-29
AU2017317575B2 (en) 2021-10-14
JP2019524860A (ja) 2019-09-05
AU2017317575A1 (en) 2019-03-28
CA3034956A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
EA036757B1 (ru) Фармацевтические композиции для комбинированной терапии
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
WO2018188536A1 (zh) 一种治疗肝纤维化的药物和治疗方法
US20230190743A1 (en) Treatment with ileal bile acid transporter (ibat) inhibitors for increased event-free survival (efs)
TW202327589A (zh) 肝病之組合療法
CN103221043B (zh) 用于治疗神经元连接发育障碍的erk抑制剂
JP7048863B2 (ja) 非アルコール性脂肪肝疾患の治療法
TW201936189A (zh) 用於使用fxr激動劑之方法
JP2024539929A (ja) 頂端側ナトリウム依存性胆汁酸輸送体阻害剤（ａｓｂｔｉ）の投薬方法
JP2002523461A (ja) 神経変性疾患の治療方法
RU2849641C1 (ru) Терапевтическое средство против жировой болезни печени
EP4166137B1 (en) Therapeutic agent for fatty liver disease
TWI906348B (zh) 脂肪性肝疾病之治療劑
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
CN121154625A (zh) 5-甲氧基邪蒿素在制备用于预防和/或治疗胆汁淤积性肝病的药物中的应用
HK40089150A (en) Therapeutic agent for fatty liver disease
HK40089150B (en) Therapeutic agent for fatty liver disease
HK40080642A (en) Therapeutic agent for fatty liver disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220118

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

R150 Certificate of patent or registration of utility model

Ref document number: 7048863

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04